| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-N-Me-Phe-OH does not have a specific pharmacological target but is used as a building block in peptide synthesis. It is a peptide inhibitor of Malaria Parasite (Plasmodium). Its N-methylated phenylalanine structure can enhance peptide stability and alter conformational properties, making it valuable for studying protein-protein interactions.
|
|---|---|
| ln Vitro |
In vitro, Fmoc-N-Me-Phe-OH is used as a building block for creating modified peptides. It serves as a peptide inhibitor of Malaria Parasite. Its incorporation into peptides provides tools for studying protein-protein interactions, enhancing stability, and modulating biological activity in pharmaceutical and biochemical research.
|
| ln Vivo |
In vivo, Fmoc-N-Me-Phe-OH is not administered as a therapeutic agent. It is used as a building block in the synthesis of peptides that may be studied in vivo for their biological activity. Its in vivo activity would depend on the peptide into which it is incorporated.
|
| Enzyme Assay |
In vitro assays for Fmoc-N-Me-Phe-OH are typically conducted in the context of peptide synthesis. It is used as a building block in solid-phase peptide synthesis (SPPS), where its incorporation into peptide chains is monitored by standard peptide chemistry techniques such as HPLC and mass spectrometry. Its activity as a peptide inhibitor of Malaria Parasite would be evaluated in parasite growth inhibition assays.
|
| Cell Assay |
Cellular assays for Fmoc-N-Me-Phe-OH are not typically performed directly on the compound itself. Its effects are studied in the context of the peptides into which it is incorporated. For example, peptides containing Fmoc-N-Me-Phe-OH may be tested for their ability to inhibit Malaria Parasite invasion or growth in infected cell cultures.
|
| Animal Protocol |
In vivo animal studies for Fmoc-N-Me-Phe-OH are not typically conducted, as it is a building block rather than a therapeutic agent. Peptides synthesized using this building block may be tested in animal models of malaria or other diseases.
|
| ADME/Pharmacokinetics |
Fmoc-N-Me-Phe-OH is a chemical reagent and does not have pharmacokinetic properties as a drug. It is not administered systemically.
|
| Toxicity/Toxicokinetics |
Fmoc-N-Me-Phe-OH is a chemical reagent and is not intended for human consumption. Standard laboratory safety precautions should be followed. It may cause skin and eye irritation. No significant toxicity data are available for this compound as a therapeutic agent.
|
| References | |
| Additional Infomation |
Fmoc-N-Me-Phe-OH (Fmoc-N-methyl-L-phenylalanine) is a protected amino acid derivative used as a building block in Fmoc-based solid-phase peptide synthesis. It has a molecular weight of 401.46 and formula C25H23NO4. The N-methyl group enhances peptide stability and modifies conformational properties. It is a peptide inhibitor of Malaria Parasite. It is not a drug and has no clinical approval.
|
| Molecular Formula |
C25H23NO4
|
|---|---|
| Molecular Weight |
401.4544
|
| Exact Mass |
401.162
|
| CAS # |
77128-73-5
|
| PubChem CID |
978356
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
595.4±39.0 °C at 760 mmHg
|
| Melting Point |
134 °C
|
| Flash Point |
313.9±27.1 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
5.89
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN([C@@H](CC1=CC=CC=C1)C(=O)O)C(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
GBROUWPNYVBLFO-QHCPKHFHSA-N
|
| InChi Code |
InChI=1S/C25H23NO4/c1-26(23(24(27)28)15-17-9-3-2-4-10-17)25(29)30-16-22-20-13-7-5-11-18(20)19-12-6-8-14-21(19)22/h2-14,22-23H,15-16H2,1H3,(H,27,28)/t23-/m0/s1
|
| Chemical Name |
(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~249.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.23 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4910 mL | 12.4549 mL | 24.9097 mL | |
| 5 mM | 0.4982 mL | 2.4910 mL | 4.9819 mL | |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
